Century Therapeutics, Inc. Interest Expense
Century Therapeutics, Inc. (IPSC) reported Interest Expense of $540.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-11-05
- Century Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $1.08M.
- Century Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. interest expense for the quarter ending 2023-06-30 was $136.00K, a 58.79% decline year-over-year.
- Century Therapeutics, Inc. interest expense for the quarter ending 2023-03-31 was $404.00K, a 28.66% increase year-over-year.
- Century Therapeutics, Inc. interest expense for fiscal 2023 was $540.00K, a 46.90% decline from fiscal 2022.
- Century Therapeutics, Inc. interest expense for fiscal 2022 was $1.02M, a 20.24% decline from fiscal 2021.
- Century Therapeutics, Inc. interest expense for fiscal 2021 was $1.27M, a 234.65% increase from fiscal 2020.
- Century Therapeutics, Inc. interest expense for fiscal 2020 was $381.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.08M derived: sum of 2 quarters · filed 2024-11-05 | $1.22M derived: sum of 3 quarters · filed 2024-11-05 | $540.00K 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $136.00K derived: sum of 2 quarters · filed 2024-11-05 | -$540.00K 10-Q · filed 2024-11-05 | $540.00K 10-Q · filed 2023-11-09 | $540.00K derived: sum of 4 quarters · filed 2024-11-05 | ||
| 2023-06-30 | $136.00K 10-Q · filed 2023-08-09 | -$540.00K 10-Q · filed 2024-08-08 | $540.00K 10-Q · filed 2023-08-09 | $540.00K derived: sum of 3 quarters · filed 2024-05-09 | $913.00K derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-03-31 | $404.00K 10-Q · filed 2024-05-09 | $404.00K derived: sum of 2 quarters · filed 2024-05-09 | $777.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.11M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $373.00K derived: sum of 2 quarters · filed 2024-03-14 | $703.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.02M 10-K · filed 2024-03-14 | $1.40M 10-K · filed 2023-03-16 | ||
| 2022-09-30 | $373.00K 10-Q · filed 2023-11-09 | $703.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.02M 10-Q · filed 2023-11-09 | $1.34M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $330.00K 10-Q · filed 2023-08-09 | $644.00K 10-Q · filed 2023-08-09 | $965.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.29M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $314.00K 10-Q · filed 2023-05-11 | $635.00K derived: sum of 2 quarters · filed 2023-05-11 | $957.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.27M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $643.00K derived: sum of 2 quarters · filed 2023-03-16 | $961.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.27M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $322.00K 10-Q · filed 2022-11-10 | $640.00K derived: sum of 2 quarters · filed 2022-11-10 | $954.00K 10-Q · filed 2022-11-10 | $1.28M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $318.00K 10-Q · filed 2022-08-11 | $632.00K 10-Q · filed 2022-08-11 | $954.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.01M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $314.00K 10-Q · filed 2022-05-16 | $636.00K derived: sum of 2 quarters · filed 2022-05-16 | $695.00K derived: sum of 3 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $322.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $381.00K derived: sum of 2 quarters · filed 2022-03-17 | $381.00K 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $59.00K 10-Q · filed 2021-11-10 | $59.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |